Two new studies indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis (LMD), a rare but serious complication of cancer that has spread to the brain and/or spinal cord. The research, which was led ...
Oct 21, 2021
0
65
During the virtual 2021 Annual Congress of the European Society for Medical Oncology (ESMO), 16-21 September, research (co) led by VHIO investigators revealed promising advances in the treatment of metastatic breast cancer. ...
Sep 20, 2021
0
3
Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains ...
Sep 13, 2021
0
3
A study of 2,804 patients with stage I to stage III malignant pleural mesothelioma (MPM) found significant variability in access to care and a positive association between multimodality treatment, income levels, and survival ...
Sep 12, 2021
0
4
Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases. ...
Sep 10, 2021
0
2
Patients with metastatic non-small cell lung cancer (mNSCLC) who received a combined regimen of durvalumab, tremelimumab, and chemotherapy experienced a statistically significant improvement in progression-free survival and ...
Sep 9, 2021
0
0
Evidence is growing that living in areas of high greenness, surrounded by trees, shrubs and other vegetation, has beneficial effects on human health. Researchers at the University of Louisville's Christina Lee Brown Envirome ...
Aug 31, 2021
0
5
(HealthDay)—For patients with clear-cell renal cell carcinoma at high risk for recurrence after nephrectomy, adjuvant therapy with pembrolizumab improves disease-free survival, according to a study published in the Aug. ...
Aug 19, 2021
0
13
Patients with metastatic melanoma that had relapsed on anti-PD-1 therapies or BRAF/MEK inhibitors did not respond as well to an investigational therapy that involves the adoptive cell transfer of tumor-infiltrating lymphocytes ...
Aug 19, 2021
0
47
(HealthDay)—For patients with ERBB2-negative breast cancer, two years of treatment with celecoxib as adjuvant to conventional therapy yields no disease-free survival (DFS) benefits compared with placebo, according to a ...
Jul 16, 2021
0
1
